Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Doximity, Inc. (DOCS) SEC filings page provides access to the company’s official regulatory disclosures as a New York Stock Exchange–listed issuer. Doximity files annual, quarterly, and current reports that describe its financial condition, results of operations, governance matters, and material events affecting the business.
In its filings and related press releases, Doximity presents condensed consolidated balance sheets, statements of operations, and statements of cash flows, along with discussions of non-GAAP financial measures. The company explains how it calculates metrics such as non-GAAP gross profit, non-GAAP net income, adjusted EBITDA, and free cash flow, and provides reconciliations to GAAP results. These documents allow readers to see how Doximity evaluates its performance beyond standard accounting measures.
Current reports on Form 8-K for DOCS include items such as quarterly earnings announcements, changes in executive roles, annual meeting voting results, and legal developments. For example, Doximity has filed 8-Ks to furnish earnings press releases, to report the outcomes of its annual meeting of stockholders, to disclose changes in its general counsel and related roles, and to describe a securities litigation settlement agreement that remains subject to court approval and other customary conditions.
Through its proxy materials and related filings, Doximity also reports on corporate governance topics, including the election of directors, ratification of its independent registered public accounting firm, and advisory votes on executive compensation. Voting results, including the participation of Class A and Class B common stock, are detailed in these documents.
On this page, AI-powered tools can summarize lengthy DOCS filings, highlight key sections on revenue trends, profitability, cash flows, and risk disclosures, and surface notable items such as settlement agreements or executive transitions. Users can quickly review quarterly reports, annual reports, and Form 4 and other transaction-related filings, while relying on real-time updates from the SEC’s EDGAR system to follow new disclosures from Doximity, Inc.
Doximity, Inc. director Form 4 shows option exercise, share conversion, and a small sale under a preset plan. On 01/02/2026, the reporting person exercised a stock option for 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, receiving an equivalent 2,000 Class B shares that are convertible into Class A shares.
That same day, 2,000 shares of Class B Common Stock converted into 2,000 shares of Class A Common Stock, and 2,000 Class A shares were sold at a price of $44.65 per share. After these transactions, the director beneficially owned 19,839 shares of Class A Common Stock directly and held 460,700 derivative securities in the form of stock options. The filing notes that the sale was made automatically under a Rule 10b5-1 trading plan adopted on November 12, 2024, indicating the trades were pre-arranged.
A shareholder of Doximity has filed a notice under Rule 144 to sell 2,000 shares of Doximity common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $89,300. These shares were acquired on the same date via a stock option exercise paid in cash.
Over the prior three months, the same seller disposed of an additional 4,000 common shares in two transactions, generating gross proceeds of $101,420 and $132,880. The filing notes that Doximity had 137,373,858 common shares outstanding at the time referenced, providing context for the size of the planned sale.
Doximity, Inc. reported that it has entered into an Agreement of Settlement to resolve a securities litigation case pending in the U.S. District Court for the Northern District of California. The proposed settlement calls for an aggregate payment of $31 million, which will be fully funded by insurance proceeds rather than by the company directly. If approved by the court and all conditions are met, all claims against Doximity and the named directors and officers will be dismissed without any admission of liability, fault or wrongdoing. The settlement is still subject to stockholder notice, court approval, and other customary conditions, and the company notes that appeals, opt-outs by individual plaintiffs, or issues with insurance carriers could affect the final outcome.
Doximity, Inc. director Form 4 shows an option exercise, share conversion and a small stock sale. On 12/01/2025, the reporting director exercised a stock option to acquire 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, which then converted into 2,000 shares of Class A Common Stock. The director sold 2,000 Class A shares at a price of $50.71 per share under a pre-set Rule 10b5-1 trading plan adopted on November 12, 2024. After these transactions, the director directly owned 19,839 shares of Class A Common Stock and held derivative securities representing 462,700 shares of Class B Common Stock, which are convertible into Class A shares under specified conditions.
Doximity insider files notice to sell common stock under Rule 144. The filing reports a planned sale of 2,000 shares of Doximity common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $101,420.00. These 2,000 shares were acquired on 12/01/2025 via a stock option exercise paid in cash on the same date. Common shares outstanding are listed as 137,373,858.
The filer also discloses prior sales over the past three months: 2,000 common shares on 11/03/2025 for gross proceeds of $132,880.00, 2,000 shares on 10/01/2025 for $140,020.00, and 2,000 shares on 09/02/2025 for $133,140.00. The signer represents that they are not aware of undisclosed material adverse information about Doximity.
Doximity, Inc. (DOCS)11/21/2025. The director converted 10,000 shares of Class B Common Stock into Class A Common Stock and then sold 10,000 shares of Class A Common Stock at $50 per share.
The filing notes that the sale occurred automatically under a Rule 10b5-1 trading plan adopted on February 13, 2025. After these transactions, the director directly owned 3,221 shares of Class A Common Stock and held 333,500 derivative securities, including stock options originally granted on September 2, 2020.
A shareholder of DOCS has filed a Form 144 notice to sell up to 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE. The planned sale has an aggregate market value of $500,000, and the filing notes that 137,373,858 shares of common stock are outstanding.
The 10,000 shares to be sold were acquired on 11/21/2025 via a stock option exercise from the issuer, paid in cash on the same date. Over the prior three months, the same seller, Timothy Cabral, reported sales of 20,000 shares of common stock on 09/24/2025 for gross proceeds of $1,500,000 and 6,360 shares on 09/02/2025 for gross proceeds of $421,655.28.
Doximity, Inc. (DOCS)
Doximity, Inc. reported an insider tax-withholding transaction by its Chief Executive Officer. On 11/15/2025, the CEO, who is also a director and 10% owner, had 8,005 shares of Class A Common Stock withheld by Doximity at a price of $49.62 per share. This withholding was done to cover tax obligations arising from the vesting of previously granted restricted stock units and was executed under a standing election by the company, rather than as a discretionary open-market trade by the executive. Following this transaction, the reporting person beneficially owned 2,241,053 shares of Doximity Class A Common Stock in direct ownership.
Doximity, Inc. (DOCS) director reported receiving 31,064 restricted stock units (RSUs) on November 15, 2025 under the company’s 2021 Stock Option and Incentive Plan. The RSUs vest in 10 equal quarterly installments after that date, contingent on the director’s continued service with the company at each vesting date. Each RSU converts into one share of Doximity Class A common stock at settlement, awarded at a stated price of $0 per share. Following this grant, the director beneficially owns 50,903 shares of Doximity Class A common stock in total.
FAQ
What is the current stock price of Doximity (DOCS)?
What is the market cap of Doximity (DOCS)?
